Covalon Technologies (OTCMKTS:CVALF – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.
Analyst Recommendations
This is a summary of recent recommendations for Covalon Technologies and Beta Bionics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Covalon Technologies | 0 | 0 | 0 | 0 | 0.00 |
| Beta Bionics | 1 | 3 | 6 | 1 | 2.64 |
Beta Bionics has a consensus price target of $20.30, indicating a potential upside of 28.08%. Given Beta Bionics’ stronger consensus rating and higher probable upside, analysts plainly believe Beta Bionics is more favorable than Covalon Technologies.
Volatility & Risk
Earnings & Valuation
This table compares Covalon Technologies and Beta Bionics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Covalon Technologies | $23.43 million | 1.82 | $1.47 million | $0.04 | 38.50 |
| Beta Bionics | $100.25 million | 7.05 | -$73.20 million | ($1.51) | -10.50 |
Covalon Technologies has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Covalon Technologies and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Covalon Technologies | 5.05% | 5.77% | 4.82% |
| Beta Bionics | -60.27% | -23.00% | -20.55% |
Summary
Beta Bionics beats Covalon Technologies on 7 of the 13 factors compared between the two stocks.
About Covalon Technologies
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company’s direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Covalon Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covalon Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
